These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17874825)

  • 1. Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin.
    Murakami Y; Koyabu T; Kawashima A; Kakibuchi N; Kawakami T; Takaguchi K; Kita K; Okita M
    J Nutr Sci Vitaminol (Tokyo); 2007 Jun; 53(3):213-8. PubMed ID: 17874825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin.
    Murakami Y; Nagai A; Kawakami T; Hino K; Kitase A; Hara Y; Okuda M; Okita K; Okita M
    Nutrition; 2006 Feb; 22(2):114-22. PubMed ID: 16459223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial.
    Suzuki H; Takagi H; Sohara N; Kanda D; Kakizaki S; Sato K; Mori M;
    World J Gastroenterol; 2006 Feb; 12(8):1265-9. PubMed ID: 16534882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eicosapentaenoic acid supplementation for chronic hepatitis C patients during combination therapy of pegylated interferon alpha-2b and ribavirin.
    Kawashima A; Tsukamoto I; Koyabu T; Murakami Y; Kawakami T; Kakibuchi N; Takaguchi K; Kita K; Okita M
    Lipids; 2008 Apr; 43(4):325-33. PubMed ID: 18320252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
    Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
    Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C.
    Takagi H; Nagamine T; Abe T; Takayama H; Sato K; Otsuka T; Kakizaki S; Hashimoto Y; Matsumoto T; Kojima A; Takezawa J; Suzuki K; Sato S; Mori M
    J Viral Hepat; 2001 Sep; 8(5):367-71. PubMed ID: 11555194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
    Nadeem A; Hussain MM; Aslam M; Hussain T; Butt IF; Ali Khan S; Asad A
    J Ayub Med Coll Abbottabad; 2009; 21(2):103-6. PubMed ID: 20524482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.
    Malaguarnera M; Vacante M; Giordano M; Motta M; Bertino G; Pennisi M; Neri S; Malaguarnera M; Li Volti G; Galvano F
    World J Gastroenterol; 2011 Oct; 17(39):4414-20. PubMed ID: 22110268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary study of combination therapy with interferon-alpha and zinc in chronic hepatitis C patients with genotype 1b.
    Nagamine T; Takagi H; Takayama H; Kojima A; Kakizaki S; Mori M; Nakajima K
    Biol Trace Elem Res; 2000; 75(1-3):53-63. PubMed ID: 11051596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
    Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
    Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients.
    Farias MS; Budni P; Ribeiro CM; Parisotto EB; Santos CE; Dias JF; Dalmarco EM; Fröde TS; Pedrosa RC; Wilhelm Filho D
    Gastroenterol Hepatol; 2012; 35(6):386-94. PubMed ID: 22608494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of eicosapentaenoic acid supplementation in the treatment of chronic hepatitis C patients.
    Tomioka K; Kakibuchi N; Murakami Y; Kawakami T; Takaguchi K; Kita K; Okita M
    J Nutr Sci Vitaminol (Tokyo); 2005 Dec; 51(6):419-25. PubMed ID: 16521701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
    Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
    J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
    New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Vilar Gomez E; Gra Oramas B; Soler E; Llanio Navarro R; Ruenes Domech C
    Liver Int; 2007 Mar; 27(2):247-59. PubMed ID: 17311621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.